{"id":729832,"date":"2023-02-08T16:05:07","date_gmt":"2023-02-08T21:05:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-5\/"},"modified":"2023-02-08T16:05:07","modified_gmt":"2023-02-08T21:05:07","slug":"nurix-therapeutics-to-participate-in-upcoming-investor-conferences-5","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-5\/","title":{"rendered":"Nurix Therapeutics to Participate in Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SAN FRANCISCO, Feb.  08, 2023  (GLOBE NEWSWIRE) &#8212; Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that Arthur T. Sands, M.D., Ph.D., Nurix\u2019s president and chief executive officer, and Gwenn M. Hansen, Ph.D., Nurix\u2019s chief scientific officer, will participate in the following conferences in February:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:12pt\">\n          <strong>SVB Securities Global Biopharma Conference (Virtual)<\/strong><br \/>\n          <br \/>Fireside chat: Wednesday, February 15, 4:20 \u2013 5:00 p.m. ET<br \/>Speaker: Arthur T. Sands, M.D., Ph.D.<\/li>\n<li style=\"margin-bottom:12pt\">\n          <strong>Wells Fargo Targeted Protein Degradation Virtual Summit<\/strong><br \/>\n          <br \/>Tuesday, February 21 <\/p>\n<ul type=\"circle\">\n<li style=\"margin-bottom:12pt\">Panel Topic: <em>Overcoming Resistance with Targeted Protein Degradation<\/em>\n<ul type=\"square\">\n<li style=\"margin-bottom:12pt\">8:00 \u2013 8:45 a.m. ET<\/li>\n<li style=\"margin-bottom:12pt\">Panelist: Arthur T. Sands, M.D., Ph.D.<\/li>\n<\/ul>\n<\/li>\n<li style=\"margin-bottom:12pt\">Panel Topic: <em>Degradation vs. Inhibition \u2013 When Does Targeted Protein Degradation Make Sense and When Does It Not?<\/em>\n<ul type=\"square\">\n<li style=\"margin-bottom:12pt\">1:00 \u20131:45 p.m. ET<\/li>\n<li style=\"margin-bottom:12pt\">Panelist: Gwenn M. Hansen, Ph.D.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>The events will be webcast live and may be accessed via a link in the Investors section of the Nurix website under Events and Presentations. Archived copies of the webcasts will be available on the Nurix website for approximately 30 days after the event.<\/p>\n<p>\n        <strong>About Nurix <\/strong><br \/>\n        <br \/>Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule and cell therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix\u2019s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix\u2019s wholly owned pipeline includes targeted protein degraders of Bruton\u2019s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California. For additional information visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=65B06r9NQGMfTV8o99miqBeuTvZ_W12hyYyQTH4Jke951C2-OC-2ky4LP-aL5b3bJ8SxV1rxGKW1R6eehCg4_Y6qe-S0JIgXQpUav9vVrAA=\" rel=\"nofollow noopener\" target=\"_blank\">http:\/\/www.nurixtx.com<\/a>.<\/p>\n<p>\n        <strong>Contacts:<\/strong>\n      <\/p>\n<p>\n        <strong>Investors<\/strong><br \/>\n        <br \/>Silinda Neou<br \/>Nurix Therapeutics<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kakLxPkq762IVkFYkV5bDjUssw593gsPkZcV3ohSOggjFbpKn0ocgkMi_kFCOSTDSPvL-WOKShp3aAE2uC1f4w==\" rel=\"nofollow noopener\" target=\"_blank\">ir@nurixtx.com<\/a><\/p>\n<p>Elizabeth Wolffe, Ph.D.<br \/>Wheelhouse Life Science Advisors<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zet6ZWwvCa4ewrz0UGBVsrUE8U53E394j5htu586WpSbccCBqmEsPzFUE00AwTWz8ai2mes5OyfW9D5NnpveZ9RIat4ZSg_In_J7qkrZOZ0=\" rel=\"nofollow noopener\" target=\"_blank\">lwolffe@wheelhouselsa.com<\/a><\/p>\n<p>\n        <strong>Media<\/strong><br \/>\n        <br \/>Aljanae Reynolds<br \/>Wheelhouse Life Science Advisors<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NOJVLdALu43UJZi0hksA1gm49pn8k_nl1BGPWDL9v_d90GJEwj6X5n7oND0Q87zWERGc-6RXjN6niuAzdxsw9zuV4yHUtDWRu4M3tXhRTilzxUKxxF4m1v8wQa8j6K1t\" rel=\"nofollow noopener\" target=\"_blank\">areynolds@wheelhouselsa.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MjEyMyM1Mzg5ODUyIzIyMDA2Njk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/YzY4Nzk0ZWEtN2NjOC00NjNiLWI2MDgtMjU1YTA3ODlmMjQ2LTEyMTIyMjI=\/tiny\/Nurix-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN FRANCISCO, Feb. 08, 2023 (GLOBE NEWSWIRE) &#8212; Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that Arthur T. Sands, M.D., Ph.D., Nurix\u2019s president and chief executive officer, and Gwenn M. Hansen, Ph.D., Nurix\u2019s chief scientific officer, will participate in the following conferences in February: SVB Securities Global Biopharma Conference (Virtual) Fireside chat: Wednesday, February 15, 4:20 \u2013 5:00 p.m. ETSpeaker: Arthur T. Sands, M.D., Ph.D. Wells Fargo Targeted Protein Degradation Virtual Summit Tuesday, February 21 Panel Topic: Overcoming Resistance with Targeted Protein Degradation 8:00 \u2013 8:45 a.m. ET Panelist: Arthur T. Sands, M.D., Ph.D. Panel Topic: Degradation vs. Inhibition \u2013 When &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-5\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Nurix Therapeutics to Participate in Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-729832","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nurix Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-5\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nurix Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN FRANCISCO, Feb. 08, 2023 (GLOBE NEWSWIRE) &#8212; Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that Arthur T. Sands, M.D., Ph.D., Nurix\u2019s president and chief executive officer, and Gwenn M. Hansen, Ph.D., Nurix\u2019s chief scientific officer, will participate in the following conferences in February: SVB Securities Global Biopharma Conference (Virtual) Fireside chat: Wednesday, February 15, 4:20 \u2013 5:00 p.m. ETSpeaker: Arthur T. Sands, M.D., Ph.D. Wells Fargo Targeted Protein Degradation Virtual Summit Tuesday, February 21 Panel Topic: Overcoming Resistance with Targeted Protein Degradation 8:00 \u2013 8:45 a.m. ET Panelist: Arthur T. Sands, M.D., Ph.D. Panel Topic: Degradation vs. Inhibition \u2013 When &hellip; Continue reading &quot;Nurix Therapeutics to Participate in Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-5\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-08T21:05:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MjEyMyM1Mzg5ODUyIzIyMDA2Njk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-5\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-5\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Nurix Therapeutics to Participate in Upcoming Investor Conferences\",\"datePublished\":\"2023-02-08T21:05:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-5\\\/\"},\"wordCount\":380,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-5\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MjEyMyM1Mzg5ODUyIzIyMDA2Njk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-5\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-5\\\/\",\"name\":\"Nurix Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-5\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-5\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MjEyMyM1Mzg5ODUyIzIyMDA2Njk=\",\"datePublished\":\"2023-02-08T21:05:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-5\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-5\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-5\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MjEyMyM1Mzg5ODUyIzIyMDA2Njk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MjEyMyM1Mzg5ODUyIzIyMDA2Njk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-5\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nurix Therapeutics to Participate in Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nurix Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-5\/","og_locale":"en_US","og_type":"article","og_title":"Nurix Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk","og_description":"SAN FRANCISCO, Feb. 08, 2023 (GLOBE NEWSWIRE) &#8212; Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that Arthur T. Sands, M.D., Ph.D., Nurix\u2019s president and chief executive officer, and Gwenn M. Hansen, Ph.D., Nurix\u2019s chief scientific officer, will participate in the following conferences in February: SVB Securities Global Biopharma Conference (Virtual) Fireside chat: Wednesday, February 15, 4:20 \u2013 5:00 p.m. ETSpeaker: Arthur T. Sands, M.D., Ph.D. Wells Fargo Targeted Protein Degradation Virtual Summit Tuesday, February 21 Panel Topic: Overcoming Resistance with Targeted Protein Degradation 8:00 \u2013 8:45 a.m. ET Panelist: Arthur T. Sands, M.D., Ph.D. Panel Topic: Degradation vs. Inhibition \u2013 When &hellip; Continue reading \"Nurix Therapeutics to Participate in Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-5\/","og_site_name":"Market Newsdesk","article_published_time":"2023-02-08T21:05:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MjEyMyM1Mzg5ODUyIzIyMDA2Njk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-5\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-5\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Nurix Therapeutics to Participate in Upcoming Investor Conferences","datePublished":"2023-02-08T21:05:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-5\/"},"wordCount":380,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-5\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MjEyMyM1Mzg5ODUyIzIyMDA2Njk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-5\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-5\/","name":"Nurix Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-5\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-5\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MjEyMyM1Mzg5ODUyIzIyMDA2Njk=","datePublished":"2023-02-08T21:05:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-5\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-5\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-5\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MjEyMyM1Mzg5ODUyIzIyMDA2Njk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MjEyMyM1Mzg5ODUyIzIyMDA2Njk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-5\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Nurix Therapeutics to Participate in Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/729832","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=729832"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/729832\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=729832"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=729832"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=729832"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}